Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
01 2Granules India Limited
02 1AX Pharmaceutical Corp
03 1Aurobindo Pharma Limited
04 1Cambrex Profarmaco Milano S.r.l.
05 1Clarochem Ireland Ltd.
06 1Hetero Drugs Limited
07 1LUPIN LIMITED
08 2MSN Laboratories Private Limited
09 3Olon SpA
10 1Optimus Drugs Private Limited
11 1Willow Birch Pharma, Inc.
01 3RIFAXIMIN
02 11Rifaximin
03 1rifaximin
01 1Canada
02 8India
03 1Ireland
04 3Italy
05 2U.S.A
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-017
Start Marketing Date : 2021-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-020
Start Marketing Date : 2023-08-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12828-0089
Start Marketing Date : 2016-11-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57297-029
Start Marketing Date : 2010-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14501-0021
Start Marketing Date : 2015-04-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14501-0093
Start Marketing Date : 2014-03-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0043
Start Marketing Date : 2012-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0044
Start Marketing Date : 2012-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17337-0032
Start Marketing Date : 2012-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 10695-011
Start Marketing Date : 2016-05-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Rifaximin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rifaximin, including repackagers and relabelers. The FDA regulates Rifaximin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rifaximin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rifaximin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rifaximin supplier is an individual or a company that provides Rifaximin active pharmaceutical ingredient (API) or Rifaximin finished formulations upon request. The Rifaximin suppliers may include Rifaximin API manufacturers, exporters, distributors and traders.
click here to find a list of Rifaximin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rifaximin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rifaximin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rifaximin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rifaximin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rifaximin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rifaximin suppliers with NDC on PharmaCompass.
We have 11 companies offering Rifaximin
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
